1. Home
  2. SYRE vs LSBPW Comparison

SYRE vs LSBPW Comparison

Compare SYRE & LSBPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYRE
  • LSBPW
  • Stock Information
  • Founded
  • SYRE 2013
  • LSBPW N/A
  • Country
  • SYRE United States
  • LSBPW China
  • Employees
  • SYRE N/A
  • LSBPW 758
  • Industry
  • SYRE Biotechnology: Pharmaceutical Preparations
  • LSBPW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SYRE Health Care
  • LSBPW Health Care
  • Exchange
  • SYRE Nasdaq
  • LSBPW Nasdaq
  • Market Cap
  • SYRE N/A
  • LSBPW N/A
  • IPO Year
  • SYRE 2016
  • LSBPW N/A
  • Fundamental
  • Price
  • SYRE $23.70
  • LSBPW $0.07
  • Analyst Decision
  • SYRE Strong Buy
  • LSBPW
  • Analyst Count
  • SYRE 8
  • LSBPW 0
  • Target Price
  • SYRE $51.50
  • LSBPW N/A
  • AVG Volume (30 Days)
  • SYRE 600.7K
  • LSBPW N/A
  • Earning Date
  • SYRE 02-27-2025
  • LSBPW N/A
  • Dividend Yield
  • SYRE N/A
  • LSBPW N/A
  • EPS Growth
  • SYRE N/A
  • LSBPW N/A
  • EPS
  • SYRE N/A
  • LSBPW N/A
  • Revenue
  • SYRE N/A
  • LSBPW N/A
  • Revenue This Year
  • SYRE $168.62
  • LSBPW N/A
  • Revenue Next Year
  • SYRE $47.61
  • LSBPW N/A
  • P/E Ratio
  • SYRE N/A
  • LSBPW N/A
  • Revenue Growth
  • SYRE N/A
  • LSBPW N/A
  • 52 Week Low
  • SYRE $20.07
  • LSBPW N/A
  • 52 Week High
  • SYRE $47.97
  • LSBPW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SYRE 54.71
  • LSBPW N/A
  • Support Level
  • SYRE $21.67
  • LSBPW N/A
  • Resistance Level
  • SYRE $22.81
  • LSBPW N/A
  • Average True Range (ATR)
  • SYRE 1.42
  • LSBPW 0.00
  • MACD
  • SYRE 0.40
  • LSBPW 0.00
  • Stochastic Oscillator
  • SYRE 96.23
  • LSBPW 0.00

About LSBPW LakeShore Biopharma Co. Ltd

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

Share on Social Networks: